PD L1 News and Research

RSS
CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

CytomX closes $70 million Series D financing round

CytomX closes $70 million Series D financing round

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Combination of nivolumab and ipilimumab drugs can improve outcomes in patients with advanced melanoma

Combination of nivolumab and ipilimumab drugs can improve outcomes in patients with advanced melanoma

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

People with common form of lung cancer can benefit from nivolumab drug

People with common form of lung cancer can benefit from nivolumab drug

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.